Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695304 | 0.77 | HTR2C (0.38) | ELANEHTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL5231140 | 0.75 | HTR2C (0.38) | ELANEHTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL6691330 | 0.69 | SIGMAR1 (0.38) | ELANEHTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL10645739 | 0.69 | ELANE (0.56) | ELANEBACE1KMT2ATSHRMAPT | |
| SCHEMBL8489022 | 0.69 | HTR6 (0.39) | ELANEHTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL5230057 | 0.68 | ALDH1A1 (0.37) | HTR2CHTR2AHTR2BCYP3A4CYP1A2 | |
| SCHEMBL2870036 | 0.68 | SIGMAR1 (0.36) | ELANEHTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL5227995 | 0.67 | HTR2C (0.37) | ELANEHTR2CHTR2BCYP3A4BACE1 | |
| SCHEMBL11380638 | 0.66 | CYP2D6 (0.39) | HTR2CHTR2AHTR2BSIGMAR1CYP3A4 | |
| SCHEMBL16865398 | 0.65 | ELANE (0.45) | ELANEBACE1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001970-B1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6953791-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6951850-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6924280-B2 | Dipeptide derivatives | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-RE38524-E1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2004-06-01 | — | — | US | disclosed |
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | CARPINO PHILIP ALBERT (US) | 2004-01-15 | — | — | US | disclosed |
| US-20040006063-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030216399-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2003-11-20 | — | — | US | disclosed |
| US-6525047-B2 | Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| US-6432945-B1 | Dipeptide derivatives | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6433171-B1 | FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6429313-B2 | Dipeptide derivatives | PFIZER INC. | 2002-08-06 | — | — | US | disclosed |
| US-20020065284-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020042415-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020002165-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-01-03 | — | — | US | disclosed |
| US-20010041703-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2001-11-15 | — | — | US | disclosed |
| US-6251902-B1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | GHSR, GHRHR, GIPR | ELANE 924/4885HTR2C 992/4885HTR2A 563/4885 |
| US-20020042415-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | ELANE 420/4885HTR2C 1093/4885HTR2A 663/4885 |
| US-20010041703-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | ELANE 428/4885HTR2C 2168/4885HTR2A 1525/4885 |
| US-20020002165-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | ELANE 420/4885HTR2C 1093/4885HTR2A 663/4885 |
| US-20040006063-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | ELANE 468/4885HTR2C 1264/4885HTR2A 455/4885 |
| US-20030216399-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | ELANE 420/4885HTR2C 1093/4885HTR2A 663/4885 |
| US-20020065284-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | ELANE 420/4885HTR2C 1093/4885HTR2A 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.